Pila Pharma Receives EMA Go-Ahead to Start Obesity Trials for TRPV1 Antagonist XEN-D0501
核心洞察
Pila Pharma (搜索) has received EMA approval to begin a new clinical trial for XEN-D0501, its lead TRPV1 (搜索) antagonist candidate, in obesity (搜索).
XEN-D0501 is a potential first-in-class oral small molecule that has demonstrated enhanced endogenous insulin response in Phase 2a trials in overweight people with type 2 diabetes (搜索).
The candidate has been dosed in 300 humans, providing a rationale for investigating higher oral dosing in planned Phase Ib/IIa obesity (搜索) trials.
Pila Pharma (搜索) has received the go-ahead from the European Medicines Agency (EMA) to start a new clinical trial for XEN-D0501, its lead drug candidate in obesity (搜索), according to a comment published by Carlsquare Equity Research. The approval marks a key step in the company's effort to restart clinical development with a primary focus on the obesity indication.
XEN-D0501 is a potential first-in-class oral treatment that acts as a selective small molecule TRPV1 (搜索) antagonist, also known as the "chilli or capsaicin receptor." This mechanism is known to regulate neurogenic inflammation, a key factor in many diseases. The candidate has demonstrated an enhanced endogenous insulin response in Phase 2a trials conducted in overweight people with type 2 diabetes (搜索).
With a candidate dosed in 300 humans, Pila Pharma (搜索) appears to have a unique TRPV1 (搜索) antagonist profile from a safety standpoint. According to Carlsquare, the data provide a rationale for investigating higher oral dosing in the planned Phase Ib/IIa trials for the obesity (搜索) indication.
A Small Molecule in a Growing Obesity Market
Pila Pharma (搜索)'s focus is now to expand its data package by assessing XEN-D0501 in obesity (搜索). Injectable peptide solutions have established a multi-billion-dollar market, and after injectable single GLP-1 agonists and the dual agonist tirzepatide, oral therapies represent the next emerging segment in obesity drugs. Carlsquare notes that recent launches by Novo Nordisk and Eli Lilly in 2026 indicate strong demand for obesity pills.
Secondary Indications Provide Downside Protection
Given that the target, TRPV1 (搜索), is a key regulator of inflammation and pain, the company's candidate is expected to have several applications. The U.S. Food and Drug Administration (FDA) granted Pila Pharma (搜索) Orphan Drug Designation for Erythromelalgia (搜索) in July 2022, a rare and painful autoimmune disease. Currently, no targeted therapies are approved for this condition, suggesting that XEN-D0501 could be a first-in-class treatment.
Due to its small-molecule nature, Pila Pharma (搜索) could, in addition to its currently developed tablet formulation, explore a dermal or topical formulation to better align with patient needs. With a perceived potent direct anti-inflammatory effect, the application possibilities also include cardiovascular conditions, skin conditions, and other inflammatory diseases.
Preparing to Restart Clinical Development
Carlsquare believes Pila Pharma (搜索)'s valuation reflects sluggish sentiment toward early-stage Nordic biotech companies. The preclinical obesity (搜索) studies initiated in 2025 could not be conducted with the intended formulation, and the results were inconclusive, creating some uncertainty. As a result, the subscription rate in the TO2 warrant program was low.
Carlsquare sees a clear road to higher valuation when Pila Pharma (搜索) restarts its clinical development with a primary focus on obesity (搜索). The company is preparing a clinical trial application (CTA), suggesting a trial start in 6-12 months. Carlsquare's base-case valuation is SEK 2.5 per share, after expected financing for planned clinical development. The firm views the bet on obesity as high risk/high reward, while noting that secondary indications provide some downside protection if obesity trials do not pan out.